Policy & Regulation
Clarity Pharmaceuticals begins 64/67Cu SAR-bisPSMA theranostic clinical trial in US patients with metastatic castrate resistant prostate cancer
29 July 2021 -

Clarity Pharmaceuticals, a clinical stage radiopharmaceutical company, announced on Wednesday that it has started its 64/67Cu SAR-bisPSMA theranostic clinical trial in patients with metastatic castrate resistant prostate cancer in the United States.

The company has started patient recruitment with the opening of the first clinical site at the Urology Cancer Center and GU Research Network in Omaha, Nebraska.

The SECuRE trial is a Phase I/IIa theranostic trial intended for identification and treatment of PSMA-expressing mCRPC utilising Targeted Copper Theranostics. 64Cu SAR-bisPSMA is utilised for diagnosis and for choosing patients and 67Cu SAR-bisPSMA is used for therapy. It is a multi-centre, single arm, dose escalation study with a cohort expansion planned for up to 44 patients in the US. The aim of this study is to determine the safety and efficacy of 67Cu-SAR-bisPSMA as a therapy.

Login
Username:

Password: